In last trading session, Immunic Inc (NASDAQ:IMUX) saw 0.59 million shares changing hands with its beta currently measuring 1.89. Company’s recent per share price level of $1.24 trading at $0.04 or 3.33% at ring of the bell on the day assigns it a market valuation of $111.69M. That closing price of IMUX’s stock is at a discount of -70.16% from its 52-week high price of $2.11 and is indicating a premium of 21.77% from its 52-week low price of $0.97. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.78 million shares which gives us an average trading volume of 806.33K if we extend that period to 3-months.

For Immunic Inc (IMUX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Immunic Inc (NASDAQ:IMUX) trade information

Upright in the green during last session for gaining 3.33%, in the last five days IMUX remained trading in the green while hitting it’s week-highest on Monday, 11/25/24 when the stock touched $1.24 price level, adding 4.25% to its value on the day. Immunic Inc’s shares saw a change of -17.33% in year-to-date performance and have moved 11.71% in past 5-day. Immunic Inc (NASDAQ:IMUX) showed a performance of 0.00% in past 30-days. Number of shares sold short was 3.8 million shares which calculate 2.96 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 75.2% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -303.23% in reaching the projected high whereas dropping to the targeted low would mean a loss of -303.23% for stock’s current value.

Immunic Inc (IMUX) estimates and forecasts

Statistics highlight that Immunic Inc is scoring comparatively higher than the scores of other players of the relevant industry. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 31.12% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 54.30% while estimates for its earnings growth in next 5 years are of 15.50%.

Immunic Inc (NASDAQ:IMUX)’s Major holders

Insiders are in possession of 3.44% of company’s total shares while institution are holding 65.02 percent of that, with stock having share float percentage of 67.33%. Investors also watch the number of corporate investors in a company very closely, which is 65.02% institutions for Immunic Inc that are currently holding shares of the company. BVF INC/IL is the top institutional holder at IMUX for having 8.9 million shares of worth $9.88 million. And as of 2024-06-30, it was holding 9.15 of the company’s outstanding shares.

The second largest institutional holder is AVIDITY PARTNERS MANAGEMENT LP, which was holding about 8.9 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.15 of outstanding shares, having a total worth of $9.88 million.

On the other hand, Vanguard Extended Market Index Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 1.87 shares of worth $2.32 million or 2.08% of the total outstanding shares. The later fund manager was in possession of 1.67 shares on Jun 30, 2024 , making its stake of worth around $2.07 million in the company or a holder of 1.85% of company’s stock.